查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386129

全球呼吸道病毒疫苗市场：趋势、预测与竞争分析（-2030 年）

Respiratory Virus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

呼吸道病毒疫苗的趋势与预测

预计2030年，全球呼吸道病毒疫苗市场规模将达到约135亿美元，2024年至2030年年复合成长率为7.4%。该市场的主要驱动因素是呼吸道病毒感染率上升、人们对疫苗效用的认识不断提高，以及政府加快疫苗开发和普及的支出增加。全球呼吸道病毒疫苗市场的未来前景看好，诊所、医院、诊所和药局/商店市场有商机。

呼吸道病毒疫苗市场洞察

Lucintel 预测，由于灭活/杀死的免疫反应能够刺激强烈且持久的免疫反应，预计在预测期内将出现最高增长。

在这个市场中，预计医院将在预测期内实现最高成长。

由于强大的医疗基础设施和政府资助，预计北美在预测期内将出现最高的增长。

市场规模/估计：以金额估计呼吸道病毒疫苗的市场规模（10亿美元）

趋势和预测分析：各细分市场和地区的市场趋势（2018-2023）和预测（2024-2030）

細項分析：按类型、给药途径、适应症、最终用途和地区等不同细分市场估计呼吸道病毒疫苗的市场规模（十亿美元）

区域分析：北美、欧洲、亚太地区和世界其他地区的呼吸道病毒疫苗市场细分

成长机会：按类型、给药途径、适应症、最终用途和呼吸道病毒疫苗市场区域分類的成长机会分析

策略分析：呼吸道病毒疫苗市场併购、新产品开发、竞争形势等

基于波特五力模型的产业竞争实力分析

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球呼吸道病毒疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势与预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球呼吸道病毒疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球呼吸道病毒疫苗市场：按类型
    • Inactivated/Killed
    • Live-Attenuated
    • Recombinant
  • 全球呼吸道病毒疫苗市场：依给药途径分类
    • 肌肉注射
    • 鼻内
    • 皮下的
  • 全球呼吸道病毒疫苗市场：依适应症分类
    • 流感
    • 麻疹
    • 流行性腮腺炎/德国麻疹
    • 新冠病毒
  • 全球呼吸道病毒疫苗市场：依最终用途分类
    • 诊所
    • 医院
    • 诊所
    • 药房/商店
    • 其他的

第4章市场趋势与预测分析：按地区（2018-2030）

  • 全球呼吸道病毒疫苗市场区域分布
  • 北美呼吸道病毒疫苗市场
  • 欧洲呼吸道病毒疫苗市场
  • 亚太呼吸道病毒疫苗市场
  • 其他地区呼吸道病毒疫苗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球呼吸道病毒疫苗市场成长机会
    • 按给药途径的全球呼吸道病毒疫苗市场成长机会
    • 全球呼吸道病毒疫苗市场成长机会（按适应症）
    • 全球呼吸道病毒疫苗市场成长机会（依最终用途）
    • 全球呼吸道病毒疫苗市场成长机会（按地区）
  • 全球呼吸道病毒疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球呼吸道病毒疫苗市场产能扩张
    • 全球呼吸道病毒疫苗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic
简介目录

Respiratory Virus Vaccine Trends and Forecast

The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030 with a CAGR of 7.4% from 2024 to 2030. The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.

A more than 150-page report is developed to help in your business decisions.

Respiratory Virus Vaccine by Segment

The study includes a forecast for the global respiratory virus vaccine by type, route of administration, indication, end use, and region.

Respiratory Virus Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Inactivated/Killed
  • Live-Attenuated
  • Recombinant

Respiratory Virus Vaccine Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Intramuscular
  • Intranasal
  • Subcutaneous

Respiratory Virus Vaccine Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Influenza
  • Measles
  • Mumps & Rubella
  • Coronavirus

Respiratory Virus Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Physician Offices
  • Hospitals
  • Clinics
  • Pharmacies/Stores
  • Others

Respiratory Virus Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Respiratory Virus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic

Respiratory Virus Vaccine Market Insights

Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.

Within this market, hospital is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.

Features of the Global Respiratory Virus Vaccine Market

Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).

Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the respiratory virus vaccine market size?

Answer: The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030.

Q.2 What is the growth forecast for respiratory virus vaccine market?

Answer: The global respiratory virus vaccine market is expected to grow with a CAGR of 7.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the respiratory virus vaccine market?

Answer: The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.

Q4. What are the major segments for respiratory virus vaccine market?

Answer: The future of the respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets.

Q5. Who are the key respiratory virus vaccine market companies?

Answer: Some of the key respiratory virus vaccine companies are as follows:

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic

Q6. Which respiratory virus vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.

Q7. In respiratory virus vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the respiratory virus vaccine market by type (inactivated/killed, live-attenuated, and recombinant), route of administration (intramuscular, intranasal, and subcutaneous), indication (influenza, measles, mumps & rubella, and coronavirus), end use (physician offices, hospitals, clinics, pharmacies/stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Virus Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Respiratory Virus Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Respiratory Virus Vaccine Market by Type
    • 3.3.1: Inactivated/Killed
    • 3.3.2: Live-Attenuated
    • 3.3.3: Recombinant
  • 3.4: Global Respiratory Virus Vaccine Market by Route of Administration
    • 3.4.1: Intramuscular
    • 3.4.2: Intranasal
    • 3.4.3: Subcutaneous
  • 3.5: Global Respiratory Virus Vaccine Market by Indication
    • 3.5.1: Influenza
    • 3.5.2: Measles
    • 3.5.3: Mumps & Rubella
    • 3.5.4: Coronavirus
  • 3.6: Global Respiratory Virus Vaccine Market by End Use
    • 3.6.1: Physician Offices
    • 3.6.2: Hospitals
    • 3.6.3: Clinics
    • 3.6.4: Pharmacies/Stores
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Respiratory Virus Vaccine Market by Region
  • 4.2: North American Respiratory Virus Vaccine Market
    • 4.2.2: North American Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.3: European Respiratory Virus Vaccine Market
    • 4.3.1: European Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.3.2: European Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.4: APAC Respiratory Virus Vaccine Market
    • 4.4.1: APAC Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.4.2: APAC Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.5: ROW Respiratory Virus Vaccine Market
    • 4.5.1: ROW Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.5.2: ROW Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Indication
    • 6.1.4: Growth Opportunities for the Global Respiratory Virus Vaccine Market by End Use
    • 6.1.5: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Respiratory Virus Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Respiratory Virus Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Virus Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Sanofi
  • 7.2: AstraZeneca
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Serum Institute of India
  • 7.6: Moderna
  • 7.7: Bavarian Nordic